Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan for sporadic amyotrophic lateral sclerosis
NL-OMON54376Phase 2Active, not recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Dec 2022
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pegcetacoplan in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Apellis Pharmaceuticals. Started Dec 2022; status: active, not recruiting.
02
Drugs
pegcetacoplan
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON54376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54376.